140 related articles for article (PubMed ID: 9147607)
1. Protein kinase C: a worthwhile target for anticancer drugs?
Caponigro F; French RC; Kaye SB
Anticancer Drugs; 1997 Jan; 8(1):26-33. PubMed ID: 9147607
[TBL] [Abstract][Full Text] [Related]
2. Modulation of protein kinase C in antitumor treatment.
Hofmann J
Rev Physiol Biochem Pharmacol; 2001; 142():1-96. PubMed ID: 11190577
[TBL] [Abstract][Full Text] [Related]
3. Analogs of staurosporine: potential anticancer drugs?
Gescher A
Gen Pharmacol; 1998 Nov; 31(5):721-8. PubMed ID: 9809468
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C: a target for anticancer drugs?
Mackay HJ; Twelves CJ
Endocr Relat Cancer; 2003 Sep; 10(3):389-96. PubMed ID: 14503915
[TBL] [Abstract][Full Text] [Related]
5. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
Utz I; Hofer S; Regenass U; Hilbe W; Thaler J; Grunicke H; Hofmann J
Int J Cancer; 1994 Apr; 57(1):104-10. PubMed ID: 7908658
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C targeting in antineoplastic treatment strategies.
Jarvis WD; Grant S
Invest New Drugs; 1999; 17(3):227-40. PubMed ID: 10665476
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase C inhibitors.
Swannie HC; Kaye SB
Curr Oncol Rep; 2002 Jan; 4(1):37-46. PubMed ID: 11734112
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation.
Beltran PJ; Fan D; Fidler IJ; O'Brian CA
Biochem Pharmacol; 1997 Jan; 53(2):245-7. PubMed ID: 9037258
[TBL] [Abstract][Full Text] [Related]
9. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
Gekeler V; Boer R; Uberall F; Ise W; Schubert C; Utz I; Hofmann J; Sanders KH; Schächtele C; Klemm K; Grunicke H
Br J Cancer; 1996 Sep; 74(6):897-905. PubMed ID: 8826855
[TBL] [Abstract][Full Text] [Related]
10. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.
Jarvis WD; Fornari FA; Tombes RM; Erukulla RK; Bittman R; Schwartz GK; Dent P; Grant S
Mol Pharmacol; 1998 Nov; 54(5):844-56. PubMed ID: 9804619
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C inhibitors as novel anticancer drugs.
Goekjian PG; Jirousek MR
Expert Opin Investig Drugs; 2001 Dec; 10(12):2117-40. PubMed ID: 11772309
[TBL] [Abstract][Full Text] [Related]
12. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
13. A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells.
Sharif TR; Sharif M
Int J Oncol; 1999 Feb; 14(2):327-35. PubMed ID: 9917510
[TBL] [Abstract][Full Text] [Related]
14. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
15. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
16. Staurosporine analogues - pharmacological toys or useful antitumour agents?
Gescher A
Crit Rev Oncol Hematol; 2000 May; 34(2):127-35. PubMed ID: 10799837
[TBL] [Abstract][Full Text] [Related]
17. CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
Luo W; Sharif TR; Houghton PJ; Sharif M
Cell Growth Differ; 1997 Nov; 8(11):1225-40. PubMed ID: 9372245
[TBL] [Abstract][Full Text] [Related]
18. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
Courage C; Budworth J; Gescher A
Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE
Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
